Reported 23 days ago
Pfizer's stock has seen minimal growth of 1.9% this year, prompting investors to look for catalysts to stimulate its price. Three potential drivers include: upcoming results from a key phase 1 trial for a novel obesity treatment, the anticipated announcement of a new chief scientific officer which could influence R&D directions, and the resolution of an ongoing dispute with the activist investor Starboard Value that could lead to beneficial changes for shareholders. Each of these developments has the potential to positively impact Pfizer's market performance in the near term.
Source: YAHOO